5 insiders reported 62 Form 4 transactions for Seres Therapeutics, Inc. (MCRB) over the past 18 months (most recent 2026-08-18). Recent activity: DesRosier Thomas (See Remarks) Buy 245 shares, Shaff Eric D. (Director) Buy 722 shares, Henn Matthew R (See Remarks) Buy 238 shares, Brady Kelly (See Remarks) Buy 181 shares, DesRosier Thomas (See Remarks) Sell 82 shares. Source: SEC Form 4.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-18 | DesRosier Thomas | See Remarks | Buy | 245 | $0 |
| 2026-08-18 | Shaff Eric D. | Director | Buy | 722 | $0 |
| 2026-08-18 | Henn Matthew R | See Remarks | Buy | 238 | $0 |
| 2026-08-18 | Brady Kelly | See Remarks | Buy | 181 | $0 |
| 2026-08-18 | DesRosier Thomas | See Remarks | Sell | 82 | $373 |
| 2026-08-18 | Shaff Eric D. | Director | Sell | 263 | $1,197 |
| 2026-08-18 | Henn Matthew R | See Remarks | Sell | 81 | $369 |
| 2026-08-18 | Brady Kelly | See Remarks | Sell | 64 | $291 |
| 2026-05-19 | DesRosier Thomas | See Remarks | Sell | 79 | $595 |
| 2026-05-19 | Shaff Eric D. | Director | Buy | 722 | $0 |
| 2026-05-19 | Henn Matthew R | See Remarks | Buy | 238 | $0 |
| 2026-05-19 | Brady Kelly | See Remarks | Buy | 180 | $0 |
| 2026-05-19 | DesRosier Thomas | See Remarks | Buy | 244 | $0 |
| 2026-05-19 | Shaff Eric D. | Director | Sell | 259 | $1,950 |
| 2026-05-19 | Henn Matthew R | See Remarks | Sell | 77 | $580 |
| 2026-05-19 | Brady Kelly | See Remarks | Sell | 59 | $444 |
| 2026-02-18 | Shaff Eric D. | Director | Buy | 723 | $0 |
| 2026-02-18 | Shaff Eric D. | Director | Sell | 259 | $2,194 |
| 2026-02-18 | Young Teresa L. | See Remarks | Buy | 231 | $0 |
| 2026-02-18 | Young Teresa L. | See Remarks | Sell | 75 | $635 |
| 2026-02-18 | DesRosier Thomas | See Remarks | Buy | 244 | $0 |
| 2026-02-18 | DesRosier Thomas | See Remarks | Sell | 78 | $661 |
| 2026-02-18 | Henn Matthew R | See Remarks | Buy | 239 | $0 |
| 2026-02-18 | Henn Matthew R | See Remarks | Sell | 89 | $754 |
| 2025-11-18 | Shaff Eric D. | Director | Buy | 390 | $0 |
Source: SEC Form 4 filings · as of 2026-08-18